Product
Recombinant human interleukin-2
Aliases
Aldesleukin, Proleukin
Name
PROLEUKIN
INN Name
aldesleukin
FDA Approved
Yes
1 clinical trial
2 organizations
2 indications
1 document
Indication
CancerIndication
Solid TumorClinical trial
Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T Cells (ACTolog® IMA101) Alone or in Combination With Atezolizumab in Patients With Relapsed and/or Refractory Solid CancersStatus: Completed, Estimated PCD: 2021-09-22
Organization
Clinigen LimitedDocument
DailyMed Label: PROLEUKINOrganization
Iovance Biotherapeutics, Inc